Nice, I'm guessing Cellceutix's intellectual property portfolio is no where near priced in properly, but that would of course require information on all of the associated nonpublic information they have amassed through their preclinical programs, only potential suiters would/will be privy to such information. Prurisol or B-OM brings home the bacon and we will likely learn quite a bit more about how deep this pipeline runs.